A comparative study of olanzapine and risperidone in treating patients with treatment-resistant schizophrenia
10.3760/cma.j.issn.1006-7884.2010.01.007
- VernacularTitle:奥氮平与利培酮治疗难治性精神分裂症的对照研究
- Author:
Zi-xiang SONG
1
;
De-hua TU
;
Jia PAN
;
Zhan-kui CAI
;
Tong-jun YAN
;
Li LIU
;
Liang QIANG
;
Wei-hua WANG
;
Guang-jia WANG
;
Huan-li WANG
Author Information
1. 解放军第一○二医院精神科,常州,213003
- Publication Type:Journal Article
- Keywords:
Risperidone;
Treatment outcome;
Safety;
Schizophrenia;
Olanzapine
- From:
Chinese Journal of Psychiatry
2010;43(1):24-27
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of olanzapine and risperidone in treatment of treatment-resistant schizophrenia.Methods A total of 68 patients with treatment-resistant schizophrenia were randomly assigned to olanzapine group and risperidone group, and received olanzapine or risperidone treatment for 12 weeks respectively.The efficacy and adverse events were assessed with the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale (CGI) and Treatment Emergent Symptom Scale(TESS) at week 0 and 1,2,4,8,12.Results The PANSS scores in both groups decreased significantly after treatment (P< 0.05-0.01).The PANSS total score and negative syndrome score in olanzapine group were significant lower than that in risperidone group at each time point from 2nd weekend after treatment (P<0.05 - 0.01 ).The CGI-SI score in both groups decreased significantly after treatment ( P < 0.05 - 0.01 ).The differences in CGI-SI score at each time point in both groups were not significant (P>0.05).The response rate was higher in olanzapine group than risperidone group ( P<0.05).There were similar rates of side effects between both groups(P>0.05), with olanzapine being associated with more weight gain, and risperidone with more akathisia, abnormal lactation and/or menostasia,hypermyotonia.Conclusion The results suggest olanzapine be of good efficacy and less side effects in the treatment of treatment-resistant schizophrenia in comparison with risperidone.
